Ngā hua rapu - Sukjai Traimuangpak

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial mā Dhammika Leshan Wannigama, Cameron Hurst, Phatthranit Phattharapornjaroen, Parichart Hongsing, Natchalaikorn Sirichumroonwit, Kanokpoj Chanpiwat, Ali Hosseini Rad S.M., Robin James Storer, Puey Ounjai, Phitsanuruk Kanthawee, Natharin Ngamwongsatit, Rosalyn Kupwiwat, Chaisit Kupwiwat, James Michael Brimson, Naveen Kumar Devanga Ragupathi, Somrat Charuluxananan, Asada Leelahavanichkul, Talerngsak Kanjanabuch, Paul G. Higgins, Vishnu Nayak Badavath, Mohan Amarasiri, Valérie Verhasselt, Anthony Kicic, Tanittha Chatsuwan, Kashif Pirzada, Farid Jalali, Angela M. Reiersen, Shuichi Abe, Hitoshi Ishikawa, Chanikan Tanasatitchai, Supamat Amphol, Ladda Nantawong, Prangrawee Sangchan, Varissara Sinkajarern, Thutpharritchn Phoonakh, Phornnapat Utenpattanun, Aye Mya Sithu Shein, Timporn Vitoonpong, Nichapha Chongthavonsatit, Yahya Mankong, Piyapong Chaichana, Jenjira Yaithet, Dumrongsak Pongprajak, Sukjai Traimuangpak, Gasit Saksirisampant, Phimonsiri Lamloeskittinon, Adam Hamdy, Sinthu Kosasih, Sirirat Sirirat Luk-in